In silico prediction of major drug clearance pathways by support vector machines with feature-selected descriptors

Drug Metabolism and Disposition

Volumn 42, Issue 11, 2014, Pages 1811-1819

  Toshimoto, Kouta ^a,b   Wakayama, Naomi ^c   Kusama, Makiko ^e   Maeda, Kazuya ^d   Sugiyama, Yuichi ^f   Akiyama, Yutaka ^a,b  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^b EISAI CO LTD   (Japan)

^c Laboratory of Pharmaceutical Regulatory Science   (Japan)

^d Pharmacokinetics Research Laboratory   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPRAZOLAM; AMIKACIN; AMIODARONE; AMLODIPINE; AMOXICILLIN; APREPITANT; ATAZANAVIR; ATENOLOL; ATOMOXETINE; ATORVASTATIN; BOSENTAN; BUPRENORPHINE; BUSPIRONE; CANDESARTAN; CARBAMAZEPINE; CEFALEXIN; CEFAZOLIN; CEFDINIR; CEFIXIME; CEFOTETAN; CEFUROXIME; CELECOXIB; CERIVASTATIN; CHLOROQUINE; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ORGANIC ANION TRANSPORTER; UNINDEXED DRUG;

ACCURACY; ALGORITHM; ARTICLE; COMPUTER MODEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG STRUCTURE; INTERMETHOD COMPARISON; PREDICTION; PROCESS DEVELOPMENT; SUPPORT VECTOR MACHINE; URINARY EXCRETION; VALIDATION PROCESS; COMPUTER SIMULATION; PHARMACOKINETICS; VALIDATION STUDY;

ALGORITHMS; COMPUTER SIMULATION; PHARMACOKINETICS; SUPPORT VECTOR MACHINES;

EID: 84907463343     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.057893     Document Type: Article

References (29)

1. Batista GE, Prati RC, and Monard MC (2004) A study of the behavior of several methods for balancing machine learning training data. SIGKDD Explorations 6:20-29.
2. Benet LZ, Broccatelli F, and Oprea TI (2011) BDDCS applied to over 900 drugs. AAPS J 13: 519-547.
3. Benet LZ, Oie S, and Schwartz JB (1996) Design and optimization of dosage regimens: pharmacokinetic data, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Goodman LS, Gilman A, Hardman JG, Gilman AG, and Limbird LE eds) 9th ed, pp 1707-1792, McGraw-Hill, New York.
4. Caruana R and Freitag D (1994) Greedy Attribute Selection, ICML, New Brunswick, NJ.
5. Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, Lee PW, and Tang Y (2012) admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model 52:3099-3105.
6. Emoto C, Murayama N, Rostami-Hodjegan A, and Yamazaki H (2010) Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Curr Drug Metab 11:678-685.
7. European Medicines Agency (2010) Guideline on the Investigation of Drug Interactions, European Medicines Agency, London. http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2010/05/WC500090112.pdf.
8. Ewing TJ,Makino S, Skillman AG, and Kuntz ID (2001) DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des 15:411-428.
9. Food and Drug Administration 2012 Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, Food and Drug Administration, Silver Spring, MD http://www fda.gov/downloads/Drugs/Guidance- ComplianceRegulatoryInformation/Guidances/UCM292362.pdf.
10. Hsu CW and Lin CJ (2002) A comparison of methods for multiclass support vector machines. IEEE Trans Neural Netw 13:415-425.
11. Kusama M, Toshimoto K, Maeda K, Hirai Y, Imai S, Chiba K, Akiyama Y, and Sugiyama Y (2010) In silico classification of major clearance pathways of drugs with their physiochemical parameters. Drug Metab Dispos 38:1362-1370.
12. Lewis DF and Ito Y (2010) Human CYPs involved in drug metabolism: structures, substrates and binding affinities. Expert Opin Drug Metab Toxicol 6:661-674.
13. Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26.
14. Liu Y, An A, and Huang X (2006) Boosting prediction accuracy on imbalanced datasets with SVM ensembles, in Advances in Knowledge Discovery and Data Mining (Ng WK, Kitsuregawa M, Li J, and Chang K eds), pp 107-118, Springer-Verlag, Berlin.
15. Mishra NK, Agarwal S, and Raghava GP (2010) Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule. BMC Pharmacol 10:8.
16. Obach RS, Lombardo F, and Waters NJ (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36: 1385-1405.
17. Sakiyama Y, Yuki H, Moriya T, Hattori K, Suzuki M, Shimada K, and Honma T (2008) Predicting human liver microsomal stability with machine learning techniques. J Mol Graph Model 26:907-915.
18. Sugiyama M and Müller KR (2005) Input-dependent estimation of generalization error under covariate shift. Stat Decis 23:249-279.
19. Thummel KE and Shen DD (2001) Design and optimization of dose regimens: pharmacokinetic data, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Gilman A and Goodman LS eds) 10th ed, pp 1917-2024, McGraw-Hill, New York.
20. Thummel KE, Shen DD, Isoherranen N, and Smith HE (2006) Design and optimization of dosage regimens: pharmacokinetic data, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Gilman AG, Brunton LL, Gilman A, Goodman LS, Lazo JS, and Parker KL eds) 11th ed, pp 1787-1888, McGraw-Hill, New York.
21. Tomek I (1976) Two modifications of CNN. IEEE Trans Syst Man Cybern 6:769-772.
22. van de Waterbeemd H and Gifford E (2003) ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2:192-204.
23. Vapnik VN (2000) The Nature of Statistical Learning Theory, 2nd ed, Springer-Verlag, New York.
24. Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, and El-Kattan A (2009) Physicochemical determinants of human renal clearance. J Med Chem 52:4844-4852.
25. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, and Greenblatt DJ (2000) Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493-1504.
26. Wu CY and Benet LZ (2005) Predicting drug disposition via application of BCS: transport/ absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
27. Yamashita F, Hara H, Ito T, and Hashida M (2008) Novel hierarchical classification and visualization method for multiobjective optimization of drug properties: application to structureactivity relationship analysis of cytochrome P450 metabolism. J Chem Inf Model 48:364-369.
28. Yoshida K, Maeda K, and Sugiyama Y (2013) Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms. Annu Rev Pharmacol Toxicol 53:581-612.
29. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, and Lee VH, et al. (2002) Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res 19:921-925.